The purpose of this study is to better understand how an investigational medication, QBW276, affects people with cystic fibrosis (CF).
In addition to determining QBW276’s safety and tolerability, the study will examine how the body responds to the drug. QBW276 is breathed through the mouth. It has not been approved by the Food and Drug Administration (FDA) and is currently not available for prescription or purchase. To date, 76 healthy volunteers have received inhaled QBW276 in clinical studies. Overall, QBW276 has been found to be generally safe and well tolerated without any significant adverse effects.